Saito K, Kuwayama A, Yamamoto N, Sugita K
Department of Neurosurgery, Nagoya University School of Medicine, Japan.
Neurosurgery. 1995 Apr;36(4):668-75; discussion 675-6. doi: 10.1227/00006123-199504000-00005.
The surgical treatment of large pituitary adenomas with suprasellar extensions has been controversial. To elucidate the indications for transsphenoidal surgery of large adenomas and to evaluate the techniques for removing the suprasellar portions of the tumors, surgical procedures on 100 consecutive patients with suprasellar extensions of nonfunctioning pituitary adenomas were retrospectively investigated. Patients were followed up for 1 to 12 years (mean, 4.5 yr). One hundred twenty-five transsphenoidal operations were performed on 100 patients. The removal of each suprasellar tumor was facilitated by the placement of a lumbar subarachnoid catheter and the injection of lactated Ringer's solution or saline. This method was used in 77 operations and was effective on 60 of 72 adenomas with < 30-mm suprasellar extensions (Hardy's Grades A, B, and C) but not on those that were fibrous or dumbbell-shaped. The descent of the remaining suprasellar tumor was facilitated by keeping the sella and sellar floor open with an intrasellar drain, and the subsequent removal was achieved with staged transsphenoidal operations. Of nine fibrous or dumbbell-shaped adenomas with 10- to 30-mm suprasellar extensions, gross total removal in eight was achieved by the open sella technique and two-stage transsphenoidal operation, whereas one required transcranial surgery. Adenomas with > 30-mm suprasellar or lateral extensions (Grade D) could not be removed sufficiently by transsphenoidal operations, except one adenoma for which a subtotal removal was achieved in the third staged operation. The disease-free rate 10 years after operation was 74% for all patients: 91% for Grade A, 74% for Grade B, and 61% for Grade C.(ABSTRACT TRUNCATED AT 250 WORDS)
巨大垂体腺瘤向鞍上扩展的外科治疗一直存在争议。为阐明大型腺瘤经蝶窦手术的适应证,并评估切除肿瘤鞍上部分的技术,我们回顾性研究了100例连续的无功能垂体腺瘤向鞍上扩展患者的手术过程。患者随访1至12年(平均4.5年)。对100例患者进行了125次经蝶窦手术。通过放置腰蛛网膜下腔导管并注入乳酸林格氏液或生理盐水,有助于切除每个鞍上肿瘤。该方法在77例手术中使用,对72例鞍上扩展<30mm的腺瘤(哈代分级A、B和C)中的60例有效,但对纤维状或哑铃状腺瘤无效。通过鞍内引流保持蝶鞍和鞍底开放,促进剩余鞍上肿瘤下降,随后通过分期经蝶窦手术切除。9例鞍上扩展10至30mm的纤维状或哑铃状腺瘤中,8例通过开放蝶鞍技术和两阶段经蝶窦手术实现了全切,而1例需要开颅手术。鞍上或外侧扩展>30mm(D级)的腺瘤,经蝶窦手术无法充分切除,除1例腺瘤在第三次分期手术中实现了次全切除。所有患者术后10年的无病生存率为74%:A级为91%,B级为74%,C级为61%。(摘要截短至250字)